The use of gene therapy to correct mutated or lost gene function for the treatment of human cancers has been an active, yet problematic area of biomedical research. Many technical difficulties, including efficient tissue-specific delivery, integration site specificity and general toxicity, are being addressed. Little is known, however, about the genetic and phenotypic stability that accompanies a successful gene-specific targeting event in a cancer cell. This question was addressed following the creation of a colon cancer cell line in which a mutated hMLH1 gene was corrected via targeted homologous recombination. This correction resulted in the expression of wild-type hMLH1 protein, restoration of the hPMS2 protein and mismatch repair (MMR) proficiency. One of two hMLH1-corrected clones, however, was found to retain defects in MMR activity. These cells continued to express the corrected hMLH1 protein, but had lost expression of another MMR protein, hMSH6. DNA sequence analysis of the hMSH6 gene revealed biallelic expansions of a cytosine repeat region in exon 5 that result in frameshifts leading to premature stop codons. These findings suggest that, similar to acquired drug resistance, the presence of genetically heterogeneous cancer cell populations or acquisition of compensatory mutations can result in 'resistance' to gene replacement therapy.
Introduction
Genomic instability can trigger the inactivation of tumor suppressor genes or the activation of proto-oncogenes, thus initiating carcinogenesis. Two general forms of genetic instability exist in cancer cells, chromosomal instability (CIN) and microsatellite instability (MIN). 1 MIN has been demonstrated in over 90% of hereditary non-polyposis colorectal cancers and in 10-15% of both sporadic colorectal and ovarian cancers. [2] [3] [4] MIN cancers are characterized by a defect in the mismatch repair (MMR) system, which would normally identify and excise DNA replication errors, such as base/base mismatches and insertion/deletion loops (IDLs). IDLs are caused by slippage of the DNA polymerase during the replication of microsatellite sequences, causing insertions or deletions in repetitive DNA sequences in the genome and can therefore lead to widespread genomic instability. 5 Mutations in the MMR genes hMSH2, hMLH1 and hPMS2, and to a lesser extent hMSH6, are responsible for the MIN phenotype. This finding is explained by the partial redundancy of hMSH6 and hMSH3 in the repair of IDLs. In fact, whereas base-base mismatches are almost exclusively recognized by the hMSH2/hMSH6 heterodimer, hMutSa, small IDLs can be bound either by hMutSa or the hMSH2/hMSH3 heterodimer, hMutSb. 6, 7 In terms of clinical treatment, MIN cancers tend to have increased resistance to methylating agents and chemotherapeutics such as cisplatin and carboplatin. [8] [9] [10] [11] Of greater clinical concern is the observation that cancer cells can gain a MIN phenotype and acquire resistance to such chemotherapeutics. 3 As of 2003, the Food and Drug Administration (FDA) has not designated any gene therapy approach for cancer as safe and effective. Attractive gene therapy targets tend to focus on introducing tumor suppressors or inactivating oncogenes for the purpose of slowing or stopping tumor growth. Many viral and non-viral delivery methods have been developed over the last 16 years, the most common being adenoviral and retroviral vectors. As various potential targets and delivery methods for targeted gene therapy are studied, serious problems still remain, including strong immunogenicity leading to inflammation, lack of stable integration and insertional mutagenesis leading to iatrogenic cancers. 12 Newer technologies, such as zinc-finger nucleases (ZFNs) for targeted gene correction in human cells; have shown great promise in overcoming some of these obstacles. 13, 14 What is not evident, however, are the potential efficacy problems that targeted gene therapy may encounter in the ever-changing genetic environment of the tumor.
Here, we attempted to address any phenotypic or genotypic consequences of targeted gene therapy by correcting a mutation in the hMLH1 gene in the MINpositive colon cancer cell line, HCT116. Utilizing targeted homologous recombination, we successfully corrected a non-sense mutation in exon 9 of hMLH1 that resulted in the expression of wild-type hMLH1 protein, restoration of the hMLH1 binding partner, hPMS2, and subsequent MMR proficiency. One of our hMLH1-corrected clones, however, was found to retain MMR deficiency and was later found to have lost expression of another MMR gene, hMSH6. Our findings suggest that the efficacy of targeted gene correction may be tempered by the genetic heterogeneity of cells within a tumor or by the ability of cancer cells to compensate rapidly for the detrimental effects of such a correction.
Materials and methods
Targeted correction of hMLH1 mutant exon 9 in HCT116 cells HCT116 cells (American Type Culture Collection, Manassas, VA) were cultured in McCoy's 5A modified media supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. To target the hMLH1 exon 9 locus, HCT116 cells were transfected with the linearized hMLH1 exon 9 targeting vectors using LipofectAmine (Invitrogen, Carlsbad, CA) and selected in growth medium supplemented with 0.4 mg/ml geneticin (Invitrogen, Carlsbad, CA). General aspects of targeting with bipartite Neo vectors are described by Jallepalli et al.
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Targeted homologous recombinants, as diagramed in Figure 1 , were identified by Polymerase Chain Reaction and later confirmed by genomic sequencing using one primer from the Neo gene and another from the hMLH1 locus outside the targeting arms.
Automated DNA sequence analysis Cells were harvested and genomic DNA was extracted using the QIAmp DNA Blood Mini Kit (Qiagen, Valencia, CA). Genomic DNA was PCR amplified using the following primers: hMLH1 exon 9 -forward 5 0 -CAA TTAGAGCAGTACCTGGC-3 0 and reverse 5 0 -CTTTGC CATGAGGTTTCTCC-3 0 ; hMSH6 exon 5 -forward 5 0 TATTTTGATGGGGGAGATCG 3 0 and reverse 5 0 -CTT CCTATTAAGTCACTGGC-3 0 . Automated sequence analysis of pooled hMLH1 exon 9 PCR products was performed by the University of Maryland School of Medicine Biopolymer/Genomics Core Facility using an Applied Biosystems Model 3730XL high-throughput 96-capillary sequencer. Genomic sequencing was performed using the following primer: hMLH1 exon 9 sequencing -5 0 -TGAGTGGATTTCCCATGTGG-3 0 . To obtain individual alleles for sequence analysis of hMSH6 exon 5, PCR products were cloned into the pCR2.1-TOPO vector according to manufacturer's instructions (Invitrogen, Carlsbad, CA). Approximately 20 clones (alleles) from each cell line were sequenced. Genomic sequencing of cloned hMSH6 exon 5 alleles was performed using the M13 forward and reverse primers.
Western blot analysis
Fifty micrograms of each nuclear extract were loaded on 7.5% sodium dodecyl sulfate (SDS)-polyacrylamide gels. Following electrophoretic separation of the proteins, they were transferred onto Amersham Hybond-P polyvinylidine fluoride (PVDF) membranes (GE Healthcare, Piscataway, NJ) by electroblotting at 30 V overnight at 41C in 25 mM Tris, 192 mM glycine and 20% methanol. The membrane was blocked with 5% low-fat milk in Trisbuffered saline containing 0.5% Tween-20 (TBST) (100 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween 20) for 1 h at room temperature. The membrane was then incubated for 1 h at room temperature with the following mouse monoclonal antibodies: anti-hMLH1 (no. 554072) at a 1:4000 dilution (BD Biosciences, San Jose, CA), antihPMS2 (no. 65861A) at a 1:1000 dilution (BD Biosciences, San Jose, CA), anti-hMSH6 (no. G70220) at a 1:2000 dilution (BD Biosciences, San Jose, CA), antihMSH2 (Ab-1 NA26) at a 1:500 dilution (EMD Biosciences, San Diego, CA), and anti--tubulin (no. sc-5274) at a 1:2000 dilution (Santa Cruz Biotechnology, Santa Cruz, CA). After three washes with TBST, the membrane was incubated with a peroxidase-conjugated secondary anti-mouse immunoglobulin (Ig)G antibody at a 1:5000 dilution (Sigma-Aldrich, St Louis, MO) for 1 h at room temperature and washed three times with TBST. Immunoreactive proteins were detected using Amersham ECL Western Blotting Detection Reagents (GE Healthcare, Piscataway, NJ).
In vitro MMR assay
The MMR assay and the production of MMR substrates and extracts are described in detail elsewhere. 16 Briefly, the MMR assays were carried out in 20 ml volumes, containing 20 mM Tris-HCl (pH 7.6), 110 mM KCl, 5 mM MgCl 2 , 1 mM glutathione, 50 mg/ml BSA, 0.1 mM of each dNTP, 1.5 mM ATP, 50 mg of the corresponding nuclear extract and 48 fmol (100 ng) DNA MMR substrate containing an extrahelical DT on the continuous strand and a nick 369 bp 5 0 from the deletion site. In the case of repair, the discontinuous strand will be degraded in 5 0 to 3 0 direction, and upon refill, an A will be inserted opposite the DT, and thus the recognition sequence for the restriction enzyme BglII will be restored.
The nuclear extracts were complemented with 600 fmol (160 ng) purified recombinant hMutSa or 780 fMol (140 ng) purified recombinant hMutLa as indicated. The repair reactions were incubated for 45 min at 371C and were then stopped by adding 30 ml stop solution (1.12% SDS, 41.67 mM ethylenediamine tetra acetic acid (EDTA), 83.33 mg/ml proteinase K) and incubated for additional 30 min at 371C. The DNA was purified employing the MinElute reaction cleanup kit (Qiagen, Valencia, CA). The RNA in the samples was removed by adding 2.5 mg RNase A followed by incubation for 15 min at 371C. The efficiency of repair was visualized by subjecting the purified DNA to restriction digest with the linearizing enzyme BsaI and the sensor enzyme BglII, which only cuts, if insertion occurred. The restriction fragments were separated on 1% agarose gels containing ethidium bromide and visualized on a UV transilluminator. The two fragments of 1833 and 1361 bp are indicative of repair, whereas the linearized unrepaired DNA substrate yields a 3193 bp band.
Results
The HCT116 cell line is a colorectal carcinoma cell line that exhibits a MIN phenotype. A point mutation (C755A) in exon 9 of hMLH1, a homolog of the Escherichia coli MMR gene MutL, results in a premature stop codon and the loss of hMLH1 protein in this cell line.
17 hMLH1 binds to and stabilizes another MutL homolog, hPMS2, allowing the proteins to function in MMR as the hMutLa heterodimer. Owing to the loss of hMLH1 protein in HCT116 cells, hPMS2 protein is also lost. 18 In addition, HCT116 cells contain a frameshift mutation in the E. coli MutS homolog, hMSH3, causing the loss of hMSH3 protein, and as a result, the hMSH2-hMSH3 heterodimer, hMutSb. 17, [19] [20] [21] The hMutSa heterodimer, containing hMSH2 and hMSH6, however, is still present in the HCT116 cell line.
In order to create a targeted correction of the hMLH1 gene, a previously described bipartite vector system was used to target the hMLH1 exon 9 in HCT116 cells ( Figure 1 ; Jallepalli et al 15 ) . Resulting clones were therefore termed BVEC, or bipartite vector exon 9 corrected, and were screened for the presence of a single corrected hMLH1 allele by PCR and subsequent genomic DNA and cDNA sequencing. Figure 2 shows sequencing results from the HCT116 parental cell line, as well as three neomycin resistant clones: BVEC-E2, BVEC-D9 and BVEC-F7. Parental HCT116 cells and the BVEC-F7 clone showed a single peak for the adenine base pair point mutation, C755A. These data indicated that BVEC-F7 neomycin-resistance resulted from a non-targeted integration event and therefore provided us with a control clone. Similar to BVEC-F7 cells, the vast majority of neomycin resistant clones screened were found to result from nontargeted events yielding an overall targeting frequency of 1:4000 or 0.025%. In contrast, BVEC-E2 and BVEC-D9 clones exhibited a double peak (designated 'N') at this sequence location. The appearance of a cytosine peak represents the presence of the wild-type hMLH1 allele, whereas the adenine peak represents the hMLH1 mutant allele. Therefore, targeted correction of the mutant hMLH1 exon 9 allele was found in BVEC clones E2 and D9. The neomycin-resistant cassette, which was flanked by LoxP sites, was then removed from the BVEC clones using Cre-recombinase-mediated excision (Figure 1c) . These results also indicate the presence of biallelic (C755A) exon 9 mutations, not previously described for HCT116 cells. The genetic mechanism that led to this biallelic occurrence in the HCT116 cell line is not known, but may have resulted from loss of the wildtype allele with reduplication of the mutant.
Next, we wanted to verify that targeted BVEC clones had restored hMLH1, as well as hPMS2, protein levels. Western blotting was performed to determine the protein expression of the MMR genes hMlh1, hPms2, hMsh6 and hMsh2 (Figure 3a) . LoVo (American Type Culture Collection, Manassas, VA, USA), a colorectal adenocarcinoma cell line was used as a control for hMLH1 and hPMS2 expression. In addition, the LoVo cell line is MIN, as it contains an hMsh2 mutation leading to the loss of hMSH2, hMSH6 and hMSH3. 6, 22, 23 Previous studies have shown that hMSH2 stabilizes its MutSa binding partner hMSH6, as well as its MutSb binding partner hMSH3, which accounts for the loss of all three proteins in the LoVo cell line. 18, 24 As expected, both HCT116 and BVEC-F7 maintained complete hMLH1 and hPMS2 protein loss. BVEC-E2
and BVEC-D9 clones demonstrated restored hMLH1 and hPMS2 protein levels as a result of the targeted correction of the hMLH1 gene. Surprisingly, the BVEC-D9 expression profile showed secondary MMR protein losses. hMSH6 was completely lost in the D9 clone and hMSH2 protein level was severely reduced (Figure 3a) , suggesting a decreased stability of hMSH2 in this cell line owing to the concomitant absence of hMSH6 and hMSH3.
We then investigated the MMR efficiency of the different clones compared to the HCT116 parental cell line using an established MMR assay. The only cell line found to have MMR proficiency without the addition of either hMutLa or hMutSa proteins was BVEC-E2 (Figure 3b ). This was expected as BVEC-E2 has a near full complement of MMR components, with the exception of hMSH3, after the correction of the hMLH1 mutant allele. The in vitro addition of recombinant purified hMutLa (as hMLH1 and hPMS2 are expressed, purified and added as a heterodimer and not as monomers) allowed HCT116 and BVEC-F7 extracts to become MMR proficient in our assay. These results demonstrated the functional correction of MMR in and hPMS2 while retaining the expression of the hMutSa heterodimer subunits, hMSH6 and hMSH2. The BVEC-E2 clone regained expression of both hMutLa subunits after the targeted correction of hMLH1. The BVEC-D9 clone also regained expression of hMutLa after the targeted correction of hMLH1, but showed a loss of hMSH6 expression and markedly reduced levels of hMSH2 (the hMSH2 band was more evident at longer exposure times -data not shown). The LoVo cell line, which harbors a mutant hMSH2 gene, was used as a control for expression of hMLH1 and hPMS2 and no expression of hMSH2 and hMSH6. hMSH3 was absent in LoVo and in HCT116 and its clones (data not shown). b-Tubulin was used as a loading control. (b) Nuclear extracts from each cell line alone (À), or supplemented with purified recombinant hMutLa or hMutSa as indicated, were incubated with the 5 0 DNA MMR substrate containing an insertion/deletion mismatch. Afterwards, the DNA was digested with the linearizing enzyme BsaI and the sensor enzyme BglII, which only cuts if insertion occurred. The 3193 bp band represents unrepaired linearized substrate, whereas the two fragments (1833 and 1361 bp) are indicative of repair. Figure 2 Automated sequence analysis to confirm correct hMLH1 targeting events in HCT116 clones. Direct genomic DNA sequencing of hMLH1 exon 9 was performed on parental HCT116 cells and BVEC clones. The endogenous HCT116-mutated nucleotide (C755A) is shown, changing a serine codon (TCA) to a premature stop codon (TAA) in both alleles. Black arrows point to the double peak of C and A (designated 'N' in the sequence trace) in both BVEC-E2 and BVEC-D9 clones, representing that both clones have one corrected (wild type) hMLH1 allele and one mutated allele. The BVEC-F7 clone shows C755A mutant alleles only and represents a non-targeted neomycin-resistant clone used as a control in subsequent experiments.
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BVEC-E2 cells. The extract of the BVEC-D9 clone, although positive for the correction of hMLH1 and restoration of hPMS2, was only made MMR proficient when the hMSH2-hMSH6 (hMutSa) heterodimer was added to the in vitro assay. As mentioned above, BVEC-D9 contained additional losses of MMR proteins hMSH6 and hMSH2, not seen in parental HCT116, BVEC-E2 or BVEC-F7 cells. These data suggest that the loss of hMSH6 and severe reduction of hMSH2 caused this clone to retain an MMR deficient phenotype. We then sought to elucidate the mechanism by which hMSH6 and hMSH2 proteins were lost or reduced in the BVEC-D9 clone. Our Western blots in Figure 3a showed a full loss of hMSH6 protein and a severe, but not complete loss of hMSH2. Therefore, we first decided to explore the possibility of epigenetic transcriptional silencing of hMSH6 as found by others. 25 Standard reverse transcriptase (RT)-PCR was used to assess the presence of hMSH6 transcript in the BVEC-D9 clone and was also conducted on the cDNA from hMSH6-positive HCT116, BVEC-E2 and BVEC-F7 cell lines. The amplification of a 350 bp fragment of hMSH6 showed the presence of hMSH6 transcript in every clone tested, including BVEC-D9, and therefore indicated that epigenetic transcriptional silencing was not the cause of hMSH6 protein loss in this clone (data not shown).
Previous studies have shown that a C(8)-tract in exon 5 of the hMSH6 gene can be a target of instability in MINpositive cancers. 26, 27 Expansion of this C(8)-tract can lead to premature stop codons and loss of hMSH6 protein expression. We wanted to determine whether insertions in the C(8)-tract of hMSH6 might be the cause for hMSH6 protein loss in BVEC-D9 cells. A 300 bp fragment containing the hMSH6 exon 5 C(8)-tract was amplified by PCR from the genomic DNA of HCT116, BVEC-E2 and BVEC-D9. PCR products were cloned and approximately 20 individual alleles from each cell line were sequenced with representative sequencing results shown in Figure 4 . HCT116 parental cells that express hMSH6 protein were found to harbor both wild-type C(8) and mutant C(9) alleles. hMLH1-corrected BVEC-E2 cells that also retain hMSH6 protein expression were found to have wild-type C(8) and mutant C(10) alleles. hMLH1-corrected BVEC-D9 cells exhibited a loss of hMSH6 protein and were found to contain only mutant C(9) and C(10) alleles. These data suggest that the MIN phenotype observed in the hMLH1-corrected BVEC-D9 clone resulted from the loss of hMSH6 protein expression as a consequence of biallelic mutations in the exon 5 C(8)-tract of the hMSH6 gene.
Discussion
In this study, we have successfully performed a targeted correction of the mutated DNA stability gene, hMLH1, in the colorectal cancer cell line, HCT116, thereby recapitulating possible results of targeted gene therapy. This successful targeting, using homologous recombination techniques, yielded independent clones that had reconstituted wild-type hMLH1 protein expression. One clone, BVEC-E2, regained the ability to carry out MMR, whereas another targeted clone, BVEC-D9, did not. Upon further inspection, the BVEC-D9 clone was found to have lost the expression of the hMutSa subunit
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Asp Thr Pro Pro Stop Leu Leu Arg Ala hMSH6. The cause of hMSH6 loss was found to be biallelic frame shift mutations in the hMSH6 exon 5 C(8)-tract, yielding C(9) and C(10) mutant alleles. The loss of hMutSa in this clone, therefore, resulted in the retention of the MMR-deficient phenotype upon correction of mutant hMLH1. We hypothesize that at least two possible explanations may exist for the development of the MMR-deficient BVEC-D9 clone. One explanation concerns the genetic heterogeneity of cells in a tumor population, both in vivo and in vitro. Therefore, there may exist a small population of cells within the HCT116 line that are completely devoid of all MMR proteins, including hMSH6 and hMSH2. A small number of cells would prevent the detection of these losses by the standard techniques we used such as Western blotting and pooled DNA sequencing. In agreement with our observations, Bonk et al. 20 found only C(8) and C(9) alleles in the bulk population of HCT116 cells using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to detect microsatellite instabilities in MMR-deficient cancer cells. We have also analyzed the sequence of approximately 20 cloned individual alleles of our parental HCT116 cells and found only wild-type C (8) and mutant C(9) alleles. As mentioned in our results, we also found that our MMR proficient BVEC-E2 clone harbored C(8) and C(10) alleles. By screening individual alleles of a larger number of single-cell derived clones from the HCT116 line, it could be possible that one could identify the occurrence of the biallelic hMSH6 mutations (C(9) and C(10)) found in our BVEC-D9 clone. In this case, we may have targeted the hMLH1 gene in one of these cells, by chance or by virtue of being more competent for targeted homologous recombination. If this explanation holds true, our experiment likely mimics problems that would be encountered with targeted gene therapy in genetically diverse primary tumors, resulting in the outgrowth of cancer cells with such pre-existing mutations.
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Another explanation for the observed BVEC-D9 genotype/phenotype would be a growth or survival selection process. This would involve the need for these cells to remain genetically unstable and thereby revert to an MMR-deficient phenotype through the mutation and subsequent loss of hMSH6. In support of this idea, our BVEC-E2 clone, with restored hMLH1 expression, grew more slowly than its hMLH1 corrected counterpart, BVEC-D9, which has lost hMutSa (data not shown). Along these lines, Zhang et al. 28 also observed that overexpression of wild-type hMLH1 in HCT116 cells increased apoptosis. From these observations, it can be inferred that MMR deficiency is a more advantageous condition for these cancer cells. Furthermore, the absence of hMSH3 in HCT116 cells and derived clones raises the possibility that some insertion-deletion loops could evade repair leading to subsequent microsatellite mutations, as observed for hMSH6 in the BVEC-D9 clone.
As with the first scenario, this explanation leads to possible problems with targeted gene therapy that are similar to those observed with current therapeutic modalities. Chemotherapeutic and radiation resistance in primary cancers and recurrent tumors is a critical issue in cancer treatment. The genetic instability observed in all human cancers allows for the possible rapid evolution of resistant cells that acquire compensatory mutations following treatment. It will be of interest to determine if the targeted correction of other genes in genetically unstable cancer cells yield similar results or if our findings are restricted to the correction of MMR in MIN colon cancer cells.
In conclusion, the heterogeneous cell population of tumors, as well as the ability of cancer cells to rapidly mutate and compensate for deleterious changes, needs to be taken into consideration while developing and implementing potential therapeutic strategies involving targeted gene therapy.
